Aurobindo Pharma Limited has disclosed the web-link to its Integrated Annual Report for the financial year ended March 31, 2026 (FY26), pursuant to Regulation 36(1)(b) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This disclosure precedes the company’s 39th Annual General Meeting (AGM) scheduled for Thursday, August 27, 2026, where shareholders will approve the audited financial statements and confirm an interim dividend of ₹4 per equity share.

The company notified the National Stock Exchange of India Limited and BSE Limited on August 4, 2026, that physical copies of the Annual Report have been sent only to members who have not registered email addresses with the company or depositories. For all other shareholders, the report is accessible via the company’s website or through a dedicated QR code. The disclosure ensures compliance with regulatory mandates for timely dissemination of financial information.

Key Disclosures and Shareholder Actions

Shareholders are advised to access the Integrated Annual Report 2025-26 through the following channels:

In addition to accessing the report, shareholders are urged to update their Know Your Customer (KYC) details, including PAN, postal address with pin code, email address, mobile number, bank account details, and nomination details. The Registrar and Transfer Agent (RTA), KFin Technologies Limited, has mandated that any payments, including dividends, for folios with incomplete KYC or PAN details will be made electronically only upon registration of the required information.

AGM and E-Voting Schedule

The 39th AGM will be conducted exclusively via Video Conferencing (VC) or Other Audio Visual Means (OAVM). The key dates for shareholder participation are as follows:

The Register of Members and Share Transfer Books will remain closed from August 26 to August 27, 2026. Institutional investors must submit board resolutions authorizing representatives to vote via email to the scrutinizer, M/s. RPR & Associates.

Governance and Auditor Updates

The AGM agenda includes the reappointment of Mr. K. Nithyananda Reddy and Dr. M. Madan Mohan Reddy, who retire by rotation. Additionally, the Board has recommended the appointment of M/s. RPR & Associates as the Secretarial Auditor for a term of five years, from FY27 to FY31, replacing M/s. MRR & Associates which resigned on May 21, 2026. This appointment aligns with Regulation 24A of the SEBI Listing Regulations and Section 204 of the Companies Act, 2013.

What the Numbers Show

The proactive disclosure of the Annual Report web-link underscores Aurobindo Pharma’s adherence to digital transparency norms under SEBI regulations. The emphasis on updating KYC details highlights a broader industry shift towards electronic dividend payments, reducing reliance on physical instruments. For shareholders, ensuring updated records is critical to receiving the confirmed ₹4 per share interim dividend without delay.

Source: https://lodr-files.dhan.co/lodr-inputs/Company/INE406A01037/b3cb4f5b-80cd-4b19-b8df-63e744f70c28.pdf

Aurobindo Pharma submitted its Business Responsibility & Sustainability Report (BRSR) for the financial year ended March 31, 2026, to the Bombay Stock Exchange and National Stock Exchange of India Limited on August 3, 2026. The filing, mandated under Regulation 34(2)(f) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, outlines the company’s environmental, social, and governance performance on a consolidated basis. The report highlights a renewable energy share of 18.4% against a 2030 target of 40%, while disclosing operational footprints across 151 countries and a workforce exceeding 46,000 individuals.

The submission was digitally signed by B. Adi Reddy, Company Secretary and Compliance Officer, on August 3, 2026. The disclosures cover general entity details, material risk assessments, and principle-wise performance indicators aligned with the National Guidelines on Responsible Business Conduct. M/s. Sharp & Tannan Associates provided reasonable assurance on specific identified sustainability information, including energy, water, greenhouse gas emissions, waste management, and employee safety metrics.

Operational and Workforce Overview

Aurobindo Pharma operates 31 manufacturing facilities under commercial operations, alongside 5 international plants and 57 offices globally. The company serves markets in 28 Indian states and union territories, plus 151 countries internationally, with exports contributing 91% of total turnover. The primary business activity involves the development, manufacture, and sale of Active Pharma Ingredients and Formulations, accounting for 100% of turnover.

As of March 31, 2026, the company employed 29,209 permanent employees and engaged 17,246 non-permanent workers. Women constitute 10% of permanent employees and 20% of workers. The Board of Directors includes 11% female representation. The company reported no fines, penalties, or imprisonment proceedings during the fiscal year.

Environmental Performance and Targets

The company consumed 1,70,250 MWh of renewable power in FY26, comprising 50,791 MWh from captive solar plants and 1,19,459 MWh purchased from associate companies. This represents an 18.4% share of total energy consumption. The firm aims to reach a 40% renewable energy share by 2030, with a baseline year of 2025. Additionally, Aurobindo targets a 25% reduction in carbon footprint (Scope 1 and 2) and 70% water conservation/restoration by 2030.

Waste management initiatives achieved 100% reuse or recycling of non-hazardous waste. For hazardous waste, 66% was co-processed, approaching the 2030 target of 70%. The company has achieved Zero Liquid Discharge status at four units: Apitoria Unit-1, Unit-2, Unit-3, and Unit-5. Total Scope 3 emissions were reported at 6,06,351 tCO2e, driven primarily by fuel and energy-related activities (3,64,215 tCO2e) and downstream transportation (1,26,833 tCO2e).

Material Risks and Governance

The report identifies energy management, climate change, and workforce wellbeing as material risks and opportunities. Rising energy costs and stringent regulatory targets pose cost-related risks, while energy efficiency initiatives offer potential savings. The company adheres to policies on Business Ethics, Human Rights, and Supplier Code of Conduct, extending these requirements to value chain partners. Approximately 77% of key starting material suppliers for finished dosage forms in India have been assessed against the Supplier Code of Conduct.

Corporate governance oversight is managed by the ESG and Sustainability Committee, chaired by Dr. M. Madan Mohan Reddy. The Audit Committee reviews internal audit reports covering these principles. The company confirmed compliance with applicable environmental laws and reported no significant adverse impacts from its value chain. CSR applicability is confirmed under Section 135 of the Companies Act, 2013, with a consolidated net worth of INR 37,883 Cr and turnover of INR 33,653 Cr.